Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study

on behalf of the FUTURE 1 study group

Research output: Contribution to journalArticlepeer-review

38 Scopus citations

Fingerprint

Dive into the research topics of 'Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study'. Together they form a unique fingerprint.

Medicine & Life Sciences